Conference Reports for NATAP

Back

13th CROI Conference on Retroviruses and Opportunistic Infections Denver, Colorado Feb 5-8, 2006     Efficacy and safety of Atazanavir With & Without Ritonavir in Antiretroviral-Naive Subjects (03/12/07)   Sensitive Genotypic Testing Uncovers Drug Resistance Associated with Viral Failure (03/12/07)   62% Steatosis in Coinfected; Abacavir & Nevirapine May Be Protective (03/07/06)   Origins of HIV Traced to Chimps in Cameroon (03/07/06)   Tenofovir + Lamivudine (3TC) for HBV/HIV Coinfection (03/07/06)   Starting HAART Earlier Results in Highest CD4 Count (03/02/06)   Heart Disease in HIV: Carotid IMT, measuring plaque in arteries (03/02/06)   Abacavir vs Nevirapine, Safety 1st-Line ART in Uganda (02/28/06)   Metabolic Analyses within A5095: Effect of Efavirenz against an All-nucleoside/Nucleotide Background: 3 Nukes; TDF Regimen vs EFV Regimens (02/27/06)   Tipranavir RESIST Analysis (02/27/06)   Rapid Emergence of Drug-resistant SIV in Tenofovir-treated Macaques: Implications for Tenofovir Chemoprophylaxis against HIV (02/27/06)   Projection to 2010 of trends in multi-drug resistant HIV in infectious gay men in the UK - Written by Andrew Phillips, UCL, London (02/27/06)   Early, Uninterrupted ART Is Associated with Improved Outcomes and Fewer Toxicities in the HIV Outpatient Study (HOPS) (02/23/06)   Analysis of Cardiovascular Risk Factors in the HIV Outpatient Study (HOPS) Cohort (02/23/06)   Risk of Heart Disease Appears to Level Off in Kaiser in Northern California (02/23/06)   D.A.D. Study: risk of myocardial infarction (02/22/06)   Tenofovir Associated Kidney Dysfunction: The Controversy Continues - Written for NATAP by Judith Aberg, MD, Bellevue Hospital, New York University Medical Center (02/23/06)   Tenofovir & Renal Dysfunction (02/23/06)   CLINICAL PHARMACOLOGY AT THE 13th CROI - John G. Gerber, M.D. Professor of Medicine and Pharmacology Divisions of Clinical Pharmacology and Infectious Diseases University of Colorado Health Sciences Center Denver, Colorado (02/23/06)   Hepatitis D Virus Can Worsen the Outcome of HBV-HIV Coinfected Patients (02/23/06)   Antiretroviral Pharmacology for PrEP (pre-exposure prophylaxis) - Written by Angela DM Kashuba, BScPhm, PharmD, DABCP Associate Professor of Pharmacy Director, UNC CFAR Clinical Pharmacology and Analytical Chemistry Core University of North Carolina at Chapel Hill (02/23/06)   Symposia & Plenary Reviews: 13th CROI - Written for NATAP by David Margolis, MD University of North Carolina (02/23/06)   Are We Ready For Circumcision: The Role of Circumcision as a Potential Preventive Measure to Stop the Spread of HIV Infection (02/22/06)   Pulmonary Hypertension: Another Look - Written for NATAP by Judith Aberg, MD, Bellevue Hospital, New York University Medical Center (02/21/06)   Fish Oil for Triglycerides Study (02/21/06)   Pegasys Rapid Response at Week 4 in APRICOT Yields 75-82% SVR in Genotype 1 Patients (02/21/06)   Recent Epidemic & Increase in Acute HCV: Sexual Transmission of HCV Among MSM; WHY? (02/21/06)   Sexual Transmission of Hepatitis C for MSM & Heterosexual Women Facilitated by STDs, HIV, Unsafe Sex Practices (02/21/06)   Is 24-week HCV therapy useful in coinfection? (02/21/06)   The Take Home from CROI on Body Shape - Written for NATAP By David Alain Wohl, MD - The University of North Carolina AIDS Clinical Research and Treatment Unit (02/17/06)   Treatment Interruption: you might not like the pills, but the alternative seems worse - Written for NATAP by David Margolis, MD, University of North Carolina (02/17/06)   Treatment Interruptions (STIs) - Written by Mike Youle, MD Royal Free Hospital, London, UK (02/17/06)   Lack of Effect of Acid Reducing Agents on the Pharmacokinetics (PK) of Lopinavir/Ritonavir (LPV/r) Tablet Formulation (02/16/06)   TMC114 & TMC125 at 13th CROI, TMC114 Expanded Access Program (02/16/06)   Development of Novel Orally Bioavailable CXCR4 Antagonists, KRH-3955 and KRH-3140: Binding Specificity, Pharmacokinetics and Anti-HIV-1 Activity in vivo and in vitro (02/15/06)   DAPD, NRTI - Modestly Reduced Viral Load & No Safety Issues (02/15/06)   Pharmacokinetics (PK) and antiretroviral (ARV) response to TMC114/r and TMC 125 combination in patients with high level viral resistance (02/15/06)   New PI GRL-02031, Potent Against Resistant HIV in vitro (02/15/06)   Reverset Resistance (02/15/06)   Pharmacokinetic/pharmacodynamic (PK/PD) analyses of TMC114 in the POWER 1 and POWER 2 trials in treatment-experienced HIV-infected patients (02/15/06)   Antiretrovirals at Denver: 13th CROI 2006 - "Future Seems Bright" - Written for NATAP by Mike Youle, MD, Royal Free Hospital, London, UK (02/15/06)   Week 48 Resistance Surveillance of HIV/HBV Co-Infected Patients Treated with Entecavir in Study AI463038 (02/14/06)   Schering CCR5 Vicriviroc- details on why study in treatment-naives was stopped but new dose is being explored (02/14/06)   Schering-Plough Press Release- Vicriviroc Clinical Study Results Presented at 13th Conference on Retroviruses and Opportunistic Infections (02/14/06)   Early HAART Associated with Improved Outcomes & Fewer Toxicities (02/14/06)   ARTs to Prevent HIV Sexual Transmission (02/14/06)   A Prospective, Open-label, Pilot Trial of Regimen Simplification to Atazanavir/Ritonavir Alone as Maintenance Antiretroviral Therapy after Sustained Virologic Suppression (ACTG 5201) (02/14/06)   TESTOSTERONE EFFECT ON FAT MASS & DISTRIBUTION (02/13/06)   Effect of pioglitazone on HIV-1 lipoatrophy : a randomised, double-bind, placebo-controlled trial (ANRS 113) (02/13/06)   Metformin + Rosiglitazone for Lipodystrophy -Combination Study (02/13/06)   Metformin for Lipodystrophy (02/13/06)   Prevention of Rectal SHIV Transmission in Macaques by Tenofovir/FTC Combination (02/13/06)   Tenofovir Achieves High Levels in the Genital tract of Men & Women and Reduces HIV RNA in Genital Tract of Men & Women (02/13/06)   'SMART' Study: Strategies for Management of Antiretroviral Therapy Study (02/13/06)   Schering CCR5 Drug Vicriviroc Study Continues (02/10/06)   HIV hits blacks harder in U.S., 51% of New Infections are Black, study finds (02/10/06)   TMC-125, Potent Against NNRTI Resistant HIV (02/10/06)   TMC-114 Resistance Profile (02/10/06)   Boehringer Ingelheim Announces 48-week Results from Aptivus (tipranavir) RESIST Studies: stratified RESIST results by CD4 and viral load (02/10/06)   Pioglitazone Improved Limb Lipoatrophy (02/10/06)   Gilead HIV-1 Integrase Inhibitor: GS-9137 (JTK-303) Exhibits Potent Antiviral Activity in Treatment-Naive and Experienced Patients (02/09/06)   Gilead Integrase Inhibitor: JTK-303/GS-9137, a Novel Small Molecule Inhibitor of HIV-1 Integrase: Anti-HIV Activity Profile and Pharmacokinetics in Animals (02/09/06)   Gilead Integrase Inhibitor: Safety and Pharmacokinetics of Single Oral Dose of JTK- 303/GS- 9137, a Novel HIV Integrase Inhibitor, in Healthy Volunteers (02/09/06)   Merck Integrase Inhibitor (02/09/06)   CD4 Count-Guided Therapy May Increase Risk of HIV Disease Progression (02/09/06)   Early HIV Therapy Yields Better Outcomes and Fewer Toxicities (02/09/06)   Integrase Inhibitors- 2 new drugs (02/09/06)   Analysis: Tracking the source of AIDS (02/09/06)   SPI-256, a Highly Potent HIV Protease Inhibitor with Broad Activity Against MDR (02/08/06)   HIV hits blacks harder in U.S., 51% of New Infections are Black, study finds (02/08/06)   GS9148: A Novel Nucleotide Active Against HIV-1 Variants with Drug Resistance Mutations in Reverse Transcriptase (02/08/06)   Next Generation HIV Peptide Fusion Inhibitor Candidates Achieve Potent, Durable Suppression of Virus replication in vitro and Improved Pharmacokinetic Properties (02/08/06)